50
Participants
Start Date
October 31, 2016
Primary Completion Date
April 9, 2021
Study Completion Date
June 7, 2021
Lévétiracetam
"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
Placebo
"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
Department of functional neurology and epileptology, Lyon
Hospices Civils de Lyon
OTHER